证券之星消息，截至2025年11月25日收盘，祥生医疗(688358)报收于31.8元，上涨2.12%，换手率 0.83%，成交量9338.0手，成交额2969.68万元。 11月25日的资金流向数据方面，主力资金净流入179.42万元，占总成交额6.04%，游资资金净流出 263.97万元，占总成交额8.89%，散户资金净流入84.55万元，占总成交额2.85%。 近5日资金流向一览见下表： 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 该股主要指标及行业内排名如下： | 指标 | 祥生医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 35.66亿元 | 110.31亿元 | 94 124 | | 净资产 | 14亿元 | 38.93亿元 | 90 124 | | 净利润 | 9392.05万元 | 2.12亿元 | 49 124 | | 市盈率(动) | 28.47 | 56.62 | 28 124 | | 市净率 | 2.55 | 3.87 | 57 124 | | 毛利率 | 59.82% | 51.22% | 52 124 ...

11月20日的资金流向数据方面，主力资金净流出728.02万元，占总成交额19.7%，游资资金净流入354.0 万元，占总成交额9.58%，散户资金净流入374.02万元，占总成交额10.12%。 近5日资金流向一览见下表： 证券之星消息，截至2025年11月20日收盘，祥生医疗(688358)报收于31.97元，下跌2.65%，换手率 1.02%，成交量1.14万手，成交额3696.15万元。 | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净街入 游资净占比 散户净拓入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-20 | 31.97 -2.65% | | -728.02万 | -19.70% | 354.00万 | 9.58% | 374.02万 | - 10.12% | | 2025-11-19 | 32.84 | -2.73% | र -55.91万 | -2.05% | 431.92万 | 15.81% | -376.01万 | -13.76% | | 20 ...

证券之星消息，截至2025年11月19日收盘，祥生医疗(688358)报收于32.84元，下跌2.73%，换手率 0.74%，成交量8261.0手，成交额2732.13万元。 11月19日的资金流向数据方面，主力资金净流出55.91万元，占总成交额2.05%，游资资金净流入431.92 万元，占总成交额15.81%，散户资金净流出376.01万元，占总成交额13.76%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-19 | 32.84 | -2.73% | -55.91万 | -2.05% | 431.92万 | 15.81% | -376.01万 | -13.76% | | 2025-11-18 | | 33.76 0.72% | 214.01万 | 7.51% | 97.99万 | 3.44% | -312.00万 | -10.95% | | 2025-11-17 | ...

该股主要指标及行业内排名如下： 证券之星消息，截至2025年11月17日收盘，祥生医疗(688358)报收于33.52元，下跌0.89%，换手率 0.9%，成交量1.01万手，成交额3371.48万元。 11月17日的资金流向数据方面，主力资金净流入19.5万元，占总成交额0.58%，游资资金净流入316.37 万元，占总成交额9.38%，散户资金净流出335.87万元，占总成交额9.96%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-17 | 33.52 | -0.89% | 19.50万 | 0.58% | 316.37万 | 9.38% | -335.87万 | -9.96% | | 2025-11-14 | 33.82 | 1.84% | -4.70万 | -0.09% | -408.15万 | -7.49% | 412.85万 | 7.58% | | 2025-1 ...

证券之星消息，截至2025年11月14日收盘，祥生医疗(688358)报收于33.82元，上涨1.84%，换手率 1.43%，成交量1.6万手，成交额5446.46万元。 11月14日的资金流向数据方面，主力资金净流出4.7万元，占总成交额0.09%，游资资金净流出408.15万 元，占总成交额7.49%，散户资金净流入412.85万元，占总成交额7.58%。 | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净流入 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-14 | 33.82 1.84% | -4.70万 | -0.09% | -408.15万 | -7.49% | 412.85万 | 7.58% | | 2025-11-13 | 33.21 0.76% | -199.35万 | -4.27% | -152.80万 | -3.27% | 352.15万 | 7.54% | | 2025-11-12 | 32.96 -2.66% | -1016.31万 | -14.71% ...

11月12日，祥生医疗盘中下跌2.01%，截至11:20，报33.18元/股，成交3441.28万元，换手率0.91%，总 市值37.20亿元。 资金流向方面，主力资金净流出268.70万元，大单买入500.71万元，占比14.55%，卖出769.41万元，占 比22.36%。 祥生医疗今年以来股价涨41.66%，近5个交易日跌5.47%，近20日跌0.06%，近60日跌4.38%。 责任编辑：小浪快报 祥生医疗所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：QFII持股、小盘、高派 息、融资融券、出海概念等。 截至9月30日，祥生医疗股东户数6167.00，较上期减少7.00%；人均流通股18181股，较上期增加 7.52%。2025年1月-9月，祥生医疗实现营业收入3.43亿元，同比减少5.27%；归母净利润9392.05万元， 同比减少4.56%。 分红方面，祥生医疗A股上市后累计派现4.64亿元。近三年，累计派现2.80亿元。 机构持仓方面，截止2025年9月30日，祥生医疗十大流通股东中，长城消费增值混合A（200006）、华 安宏利混合A（040005）退出十大流通股东之列。 今年 ...

11月6日，祥生医疗盘中上涨2.08%，截至10:24，报35.83元/股，成交3391.09万元，换手率0.86%，总市 值40.17亿元。 资金流向方面，主力资金净流入2.29万元，特大单买入293.67万元，占比8.66%，卖出0.00元，占比 0.00%；大单买入569.44万元，占比16.79%，卖出860.82万元，占比25.38%。 祥生医疗今年以来股价涨52.98%，近5个交易日涨5.54%，近20日涨4.22%，近60日涨7.28%。 祥生医疗所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：QFII持股、高派息、融 资融券、小盘、出海概念等。 截至9月30日，祥生医疗股东户数6167.00，较上期减少7.00%；人均流通股18181股，较上期增加 7.52%。2025年1月-9月，祥生医疗实现营业收入3.43亿元，同比减少5.27%；归母净利润9392.05万元， 同比减少4.56%。 分红方面，祥生医疗A股上市后累计派现4.64亿元。近三年，累计派现2.80亿元。 机构持仓方面，截止2025年9月30日，祥生医疗十大流通股东中，长城消费增值混合A（200006）、华 安宏利 ...

Core Viewpoint - Xiangsheng Medical (688358) experienced a decline in stock price, closing at 35.1 yuan on November 5, 2025, down 2.34% with a trading volume of 25,100 hands and a transaction amount of 89.26 million yuan [1] Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 343 million yuan, a year-on-year decrease of 5.27%, and a net profit attributable to shareholders of 93.92 million yuan, down 4.56% year-on-year [4] - In Q3 2025, the company achieved a single-quarter main revenue of 107 million yuan, a year-on-year decrease of 6.68%, while the net profit attributable to shareholders increased by 41.95% to 24.22 million yuan [4] Market Position - The total market value of Xiangsheng Medical is 3.936 billion yuan, with a net asset of 1.4 billion yuan and a net profit of 93.92 million yuan [4] - The company has a price-to-earnings ratio of 31.43 and a price-to-book ratio of 2.81, which are lower than the industry averages of 60.86 and 4.05, respectively [4] Capital Flow - On November 5, 2025, the net inflow of main funds was 5.19 million yuan, accounting for 5.82% of the total transaction amount, while retail investors had a net outflow of 16.13 million yuan, representing 18.07% of the total transaction amount [1] - The financing balance on the same day was 81.61 million yuan, with a net financing purchase of 1.24 million yuan [2] Institutional Ratings - In the last 90 days, four institutions have given buy ratings for Xiangsheng Medical, indicating positive sentiment among analysts [5]

Core Viewpoint - Xiangsheng Medical (688358) has shown a slight increase in stock price, with a closing price of 34.94 yuan on October 31, 2025, reflecting a 2.92% rise, amidst mixed capital flows from different investor types [1][2]. Financial Performance - For the first three quarters of 2025, Xiangsheng Medical reported a main revenue of 343 million yuan, a year-on-year decrease of 5.27% [3]. - The net profit attributable to shareholders was 93.92 million yuan, down 4.56% year-on-year, while the net profit after deducting non-recurring items was 86.97 million yuan, a decrease of 2.69% [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 107 million yuan, down 6.68% year-on-year, but the net profit attributable to shareholders increased by 41.95% to 24.22 million yuan [3]. Market Position and Ratios - Xiangsheng Medical's total market capitalization is 3.918 billion yuan, with a net asset value of 1.4 billion yuan [3]. - The company has a price-to-earnings (P/E) ratio of 31.28, which is significantly lower than the industry average of 62.61, indicating a potentially undervalued stock [3]. - The gross margin stands at 59.82%, higher than the industry average of 51.22%, while the net margin is 27.37%, compared to the industry average of 9.57% [3]. Capital Flow Analysis - On October 31, 2025, the net inflow of main funds was 5.57 million yuan, accounting for 7.14% of the total transaction volume, while retail investors experienced a net outflow of 1.33 million yuan [1][2]. - Over the past five days, the stock has seen fluctuations in capital flow, with varying net inflows and outflows from main funds, retail investors, and speculative funds [2]. Institutional Ratings - In the last 90 days, four institutions have provided ratings for Xiangsheng Medical, all of which are buy ratings, indicating positive sentiment from analysts [4].

Core Insights - The recent announcement from Xiangsheng Medical (688358.SH) reveals a significant change in its top ten circulating shareholders, with major global financial institutions like UBS AG and Barclays Bank PLC now included, indicating increased international interest in the company [1][2]. Group 1: Shareholder Changes - The latest data shows a notable shift in Xiangsheng Medical's top ten circulating shareholders, with UBS AG and Barclays Bank PLC becoming the eighth and ninth largest shareholders, respectively [2][3]. - This change reflects a growing recognition of Xiangsheng Medical's investment value by global capital, as these institutions have chosen to increase or establish positions in the company [2][3]. Group 2: Reasons for Foreign Investment - The influx of foreign capital is attributed to a thorough assessment of Xiangsheng Medical's fundamentals and the promising outlook of the ultrasound medical imaging sector [3]. - Xiangsheng Medical is a leading player in the ultrasound medical imaging equipment market, with a strong focus on R&D, production, and sales, which aligns with foreign investors' preference for high-quality growth stocks [3]. - The medical device sector is seen as a lucrative opportunity due to the global aging trend and increasing healthcare demands, with Xiangsheng Medical's products being competitive both domestically and internationally [3]. Group 3: Market Impact - The entry of major foreign investors like UBS and Barclays sends a strong positive signal to the market, enhancing confidence in Xiangsheng Medical's intrinsic value and growth potential [4]. - This development is expected to attract more domestic institutional and individual investors, creating a synergistic effect on capital inflow [4]. - The inclusion of well-known foreign institutions in the shareholder list elevates Xiangsheng Medical's market visibility and liquidity, providing an "international certification" that boosts its reputation in the capital market [4].